181 related articles for article (PubMed ID: 16619540)
1. Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer.
Ogawa K; Nakamura K; Onishi H; Koizumi M; Sasaki T; Araya M; Miyabe Y; Otani Y; Teshima T;
Anticancer Res; 2006; 26(2B):1319-25. PubMed ID: 16619540
[TBL] [Abstract][Full Text] [Related]
2. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
4. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
5. Radical external beam radiotherapy for prostate cancer in Japan: results of the 1999-2001 patterns of care process survey.
Ogawa K; Nakamura K; Onishi H; Sasaki T; Koizumi M; Shioyama Y; Komiyama T; Miyabe Y; Teshima T;
Jpn J Clin Oncol; 2006 Jan; 36(1):40-5. PubMed ID: 16418185
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report.
Sasaki T; Nakamura K; Shioyama Y; Ohga S; Urashima Y; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Honda H
Jpn J Clin Oncol; 2004 Jul; 34(7):420-4. PubMed ID: 15342670
[TBL] [Abstract][Full Text] [Related]
7. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
9. Does age matter in the selection of treatment for men with early-stage prostate cancer?
Konski A; Eisenberg D; Horwitz E; Hanlon A; Pollack A; Hanks G
Cancer; 2006 Jun; 106(12):2598-602. PubMed ID: 16683224
[TBL] [Abstract][Full Text] [Related]
10. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
[TBL] [Abstract][Full Text] [Related]
12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
13. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
14. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: changing trends in the patterns of care process survey.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Araya M; Mukumoto N; Teshima T; Mitsumori M;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1310-8. PubMed ID: 20950959
[TBL] [Abstract][Full Text] [Related]
15. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
[TBL] [Abstract][Full Text] [Related]
16. Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study.
Nguyen TD; Azria D; Brochon D; Poortmans P; Miller RC; Scandolaro L; Majewski W; Krengli M; Abacioglu U; Moretti L; Villa S; Akyol F; Jovenin N
Crit Rev Oncol Hematol; 2010 Apr; 74(1):66-71. PubMed ID: 19419885
[TBL] [Abstract][Full Text] [Related]
17. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: differences in the patterns of care between Japan and the United States.
Ogawa K; Nakamura K; Onishi H; Sasaki T; Koizumi M; Shioyama Y; Komiyama T; Miyabe Y; Teshima T;
Anticancer Res; 2006; 26(1B):575-80. PubMed ID: 16739323
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
19. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
20. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
